Coelho Carly de Faria, Vieira Rodolfo P, Araújo-Junior Osvaldo Soares, Lopes-Martins Pedro Sardinha Leonardo, Dos Santos Larissa Gomes, Dias Lucas Danilo, Filho Alberto Souza de Sá, Leonardo Patrícia Sardinha, Silva Sandro Dutra E, Lopes-Martins Rodrigo Alvaro Brandão
Laboratory of Biophotonics and Experimental Therapeutics-LABITEX, Universidade Evangélica de Goiás-Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, Brazil.
Laboratory of Exercise Immunology, Universidade Evangélica de Goiás-Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, Brazil.
Life (Basel). 2024 Oct 25;14(11):1373. doi: 10.3390/life14111373.
Generalized Anxiety Disorder (GAD) is a common psychiatric condition characterized by persistent and excessive worry, often accompanied by dysautonomic symptoms that significantly impact patients' well-being. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has shown potential as an anxiolytic through its partial agonism of the 5HT-1A receptor and its negative allosteric modulation of CB1 receptors, which may help mitigate the anxiogenic effects of tetrahydrocannabinol (THC). This study evaluates the impact of CBD on individuals diagnosed with various anxiety disorders, comparing its effects to placebo and conventional pharmaceutical treatments through a systematic review of randomized controlled trials (RCTs). A systematic search of RCTs published between 2013 and 2023 was conducted across three databases using the terms "cannabidiol" and "anxiety". Out of the 284 articles identified, 11 met the eligibility criteria. The studies reviewed varied widely in terms of the types of anxiety disorders and CBD dosages examined, leading to results that were often contradictory. Despite these conflicting outcomes, the data suggest that CBD may reduce anxiety with minimal adverse effects when compared to a placebo. However, further RCTs with improved methodologies, encompassing a broad range of doses and continuous CBD administration across specific anxiety disorders, are needed. Unlike previous studies and meta-analyses, this review encompasses a broader spectrum of anxiety disorders and a variety of study designs and dosages, providing a more nuanced understanding of CBD's potential efficacy across different conditions.
广泛性焦虑障碍（GAD）是一种常见的精神疾病，其特征为持续且过度的担忧，常伴有自主神经功能紊乱症状，严重影响患者的幸福感。大麻二酚（CBD）是一种从大麻中提取的非精神活性化合物，通过对5HT - 1A受体的部分激动作用以及对CB1受体的负变构调节，显示出作为抗焦虑药的潜力，这可能有助于减轻四氢大麻酚（THC）的致焦虑作用。本研究通过对随机对照试验（RCT）的系统评价，评估CBD对被诊断患有各种焦虑症的个体的影响，并将其效果与安慰剂和传统药物治疗进行比较。使用术语“大麻二酚”和“焦虑”在三个数据库中对2013年至2023年发表的RCT进行了系统检索。在识别出的284篇文章中，11篇符合纳入标准。所审查的研究在焦虑症类型和所研究的CBD剂量方面差异很大，导致结果往往相互矛盾。尽管有这些相互矛盾的结果，但数据表明，与安慰剂相比，CBD可能以最小的不良反应减轻焦虑。然而，需要进一步采用改进方法的RCT，涵盖广泛的剂量范围，并针对特定焦虑症持续给予CBD。与以往的研究和荟萃分析不同，本综述涵盖了更广泛的焦虑症类型以及各种研究设计和剂量，从而对CBD在不同情况下的潜在疗效有了更细致入微的理解。
